EA200700431A1 - Конъюгаты химически модифицированного гормона роста человека - Google Patents

Конъюгаты химически модифицированного гормона роста человека

Info

Publication number
EA200700431A1
EA200700431A1 EA200700431A EA200700431A EA200700431A1 EA 200700431 A1 EA200700431 A1 EA 200700431A1 EA 200700431 A EA200700431 A EA 200700431A EA 200700431 A EA200700431 A EA 200700431A EA 200700431 A1 EA200700431 A1 EA 200700431A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemically modified
growth hormone
human growth
conjugates
modified human
Prior art date
Application number
EA200700431A
Other languages
English (en)
Inventor
Рори Ф. Финн
Уэй Лэйо
Нед Р. Сиджел
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200700431A1 publication Critical patent/EA200700431A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

Согласно настоящему изобретению предложен химически модифицированный гормон роста человека (hGH), полученный путем связывания водорастворимого полимера с белком. Химически модифицированный белок по настоящему изобретению может иметь намного более продолжительную активность hGH, чем активность немодифицированного hGH, что дает возможность снизить дозу и создать благоприятные условия режима введения.
EA200700431A 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека EA200700431A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
EA200700431A1 true EA200700431A1 (ru) 2008-02-28

Family

ID=23295870

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200400565A EA008505B1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека
EA200700431A EA200700431A1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200400565A EA008505B1 (ru) 2001-11-20 2002-11-20 Конъюгаты химически модифицированного гормона роста человека

Country Status (25)

Country Link
EP (1) EP1453859A2 (ru)
JP (2) JP2005525302A (ru)
KR (2) KR20050044858A (ru)
CN (1) CN1608079A (ru)
AP (1) AP2004003050A0 (ru)
AU (1) AU2002356990A1 (ru)
BR (1) BR0214451A (ru)
CA (1) CA2467731A1 (ru)
CO (1) CO5580794A2 (ru)
EA (2) EA008505B1 (ru)
EC (1) ECSP045114A (ru)
GE (1) GEP20063860B (ru)
HR (1) HRP20040448A2 (ru)
HU (1) HUP0500997A2 (ru)
IL (1) IL162031A0 (ru)
IS (1) IS7268A (ru)
MA (1) MA27544A1 (ru)
MX (1) MXPA04004809A (ru)
NO (1) NO20042182L (ru)
OA (1) OA13063A (ru)
PL (1) PL374354A1 (ru)
RS (1) RS53104A (ru)
TN (1) TNSN04090A1 (ru)
WO (1) WO2003044056A2 (ru)
ZA (1) ZA200403907B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PL213322B1 (pl) * 2002-01-18 2013-02-28 Biogen Idec Inc Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008525032A (ja) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
JP2008538290A (ja) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
EP1928906A2 (en) 2005-08-30 2008-06-11 Novo Nordisk Health Care AG Liquid formulations of pegylated growth hormone
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
JP2009519942A (ja) * 2005-12-14 2009-05-21 アンブルックス，インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
EP2040757A2 (en) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
WO2009121210A1 (zh) * 2008-04-03 2009-10-08 厦门伯赛基因转录技术有限公司 双链聚乙二醇修饰的生长激素及其制备方法和应用
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
CN102131844B (zh) * 2008-07-31 2016-03-02 药华医药股份有限公司 肽-聚合物缀合物
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
WO2010030366A2 (en) * 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
BR112012014721B1 (pt) 2009-12-15 2022-06-28 Ascendis Pharma Endocrinology Division A/S Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN102834109B (zh) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
EP3215193B1 (en) 2014-11-06 2023-10-04 PharmaEssentia Corporation Dosage regimen for pegylated interferon
AU2016228555B2 (en) * 2015-03-11 2021-12-23 Nektar Therapeutics Conjugates of an IL-7 moiety and a polymer
RU2020111229A (ru) * 2015-09-18 2020-06-08 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE455171T1 (de) * 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
BR9812267B1 (pt) * 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
DK1157037T3 (da) * 1999-01-29 2003-11-24 Hoffmann La Roche GCSF-konjugater
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
TNSN04090A1 (fr) 2006-06-01
MA27544A1 (fr) 2005-10-03
IS7268A (is) 2004-05-17
MXPA04004809A (es) 2004-08-11
CO5580794A2 (es) 2005-11-30
AU2002356990A1 (en) 2003-06-10
JP2006321808A (ja) 2006-11-30
WO2003044056A2 (en) 2003-05-30
IL162031A0 (en) 2005-11-20
EP1453859A2 (en) 2004-09-08
KR20070072924A (ko) 2007-07-06
BR0214451A (pt) 2006-05-30
AP2004003050A0 (en) 2004-06-30
CN1608079A (zh) 2005-04-20
CA2467731A1 (en) 2003-05-30
NO20042182L (no) 2004-08-11
WO2003044056A3 (en) 2003-08-21
EA008505B1 (ru) 2007-06-29
HRP20040448A2 (en) 2006-02-28
OA13063A (en) 2006-11-10
PL374354A1 (en) 2005-10-17
GEP20063860B (en) 2006-06-26
HUP0500997A2 (en) 2007-11-28
JP2005525302A (ja) 2005-08-25
ECSP045114A (es) 2004-07-23
EA200400565A1 (ru) 2005-06-30
ZA200403907B (en) 2007-12-27
KR20050044858A (ko) 2005-05-13
RS53104A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
EA200700431A1 (ru) Конъюгаты химически модифицированного гормона роста человека
DK1715887T3 (da) N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf
HUP0400313A2 (hu) Új, biotechnológiai úton előállított, humán terápiára alkalmas szuperantigének
WO2005000359A3 (en) Chemically-modified human growth hormone conjugates
EP2360176A3 (en) Hybrid and tandem expression of neisserial derived proteins
MY169272A (en) Her2 antibody composition
BR0208183A (pt) Peptìdeo modificado por wt1
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
EP2107071A3 (en) Anti-EpCAM immunoglobulins
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
DK1583529T3 (da) Aminosyre-phenoxy-ethere, fremstilling og anvendelse deraf
HUP0402334A2 (hu) Módosított humán növekedési hormon
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
MXPA04000068A (es) Conjugados de progenipoyetina modificados quimicamente.
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
FR2821359B1 (fr) L'heterocarpine, une proteine fixant le ghrh humain
WO2000058438A3 (en) Conformationally constrained peptides
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
WO2004050703A8 (en) Splice variant of the human pituitary growth hormone
WO2023196880A3 (en) Human t-cell lymphotropic virus type 1 targeting proteins and methods of use